A Slow Takeoff for FDA's Brand Name Pilot Program
This article was originally published in RPM Report
FDA's pilot program for testing and approving proposed brand names is slowly beginning to gain traction-despite initial concern from drug sponsors that the new process would lead to longer review times. For early adopters, it means a chance to collaborate with FDA on what will likely become the new regulatory standard. For everyone else, it may mean being a step behind.
You may also be interested in...
A pilot program for reviewing proposed proprietary names for branded drugs and biologics has been terminated by FDA due to a lack of participation by industry. PhRMA thinks the agency should go a step further and abolish the brand name testing process altogether. Will that fly with FDA?
FDA wants industry to endorse a pilot program that would make sponsors responsible for testing proposed brand names for medication errors. Industry is concerned the process will make reviews less predictable. But sponsors should ask themselves this: what's less predictable than the current 40% rejection rate?
It's become all too common for sponsors: out-of-the-blue rejections of preferred brand names because a competitor's product sneaks through at the last minute. Now the agency is considering a policy change that would make the process more predictable.